Abstract 814P
Background
This study was to evaluate the clinical significance of pulmonary recurrence for patients who achieved complete remission after primary treatment of endometrioid endometrial cancer.
Methods
This multicenter retrospective study included patients who had undergone primary treatment for endometrial cancer at six different hospitals between 2009 and 2019. Inclusion criteria were patients with endometrioid histology and no evidence of residual disease after primary treatment including standard surgical procedure. Patients who developed pulmonary metastasis during follow-up were identified. Time to second objective disease progression (PFS2) was defined as time from the start of second-line therapy to second recurrence, and second-line overall survival (OS2) was defined as time from the start of second-line therapy to death.
Results
Of the 1074 patients who met the inclusion criteria, 90 experienced recurrences. Pulmonary recurrence was the most frequent site of first recurrence, accounting for 34.4% (31/90) of all recurrences. Isolated pulmonary recurrence accounted for 64.5% (20/31) of all pulmonary recurrences, whereas 35.5% (11/31) of patients had concurrent recurrences at other sites. The median PFS2 and OS2 of patients with isolated pulmonary recurrence were significantly longer than those with concurrent recurrences at other sites (PFS2, 17.0 vs. 9.0 months, log-rank P = 0.004; OS2, not reached vs. 28.0 months, log-rank P = 0.001). During the median follow-up period of 88.0 months, 73.7% of patients with isolated pulmonary recurrence had recurrence or progression after second-line treatment, but only 15.8% of the patients died. On the other hand, during the median follow-up period of 33.0 months, 88.9% of patients with concurrent recurrence at other sites had recurrence or progression after second-line treatment and 66.7% died. Multivariable analysis identified isolated pulmonary recurrence as an independent factor for longer OS2 (HR, 0.18; 95% CI, 0.03-0.59; P = 0.009).
Conclusions
Our study showed that isolated pulmonary recurrence is associated with prolonged OS2 in patients with recurrent endometrioid endometrial cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
748P - Outcomes for patients (pts) with advanced endometrial cancer (aEC) who completed pembrolizumab (pembro) and continued lenvatinib (LEN) in the phase III Study 309/KEYNOTE-775
Presenter: Emeline Colombo
Session: Poster session 11
750P - PFS2 and adjustment of overall survival (OS) for subsequent anticancer therapy in patients (pts) with primary advanced or recurrent endometrial cancer (pA/rEC) treated with dostarlimab plus chemotherapy or chemotherapy alone in the ENGOT-EN3-NSGO/GOG-3031/RUBY trial
Presenter: Brian Slomovitz
Session: Poster session 11
751P - Patients with endometrial cancer: Expectations and understanding of genetic counseling and hereditary carcinomas - First results of an international NOGGO/GCIG/ENGOT survey (EXPRESSION XI/IMPROVE)
Presenter: Jalid Sehouli
Session: Poster session 11
752P - Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic squamous cell cervix carcinoma: Subgroup analysis of the PEVOsq basket trial
Presenter: Olivia Le Saux
Session: Poster session 11
753P - IN10018 in combination with pegylated liposomal doxorubicin (PLD) in platinum-resistant ovarian cancer (PROC): A single-arm, phase Ib clinical trial
Presenter: Lingying Wu
Session: Poster session 11
754P - Ubamatamab (MUC16xCD3 bispecific antibody) with cemiplimab (anti-PD-1 antibody) in recurrent ovarian cancer: Phase I dose-escalation study
Presenter: Roisin O'Cearbhaill
Session: Poster session 11
755P - Retifanlimab in patients with recurrent microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) endometrial cancer: Final results from the POD1UM-101 study (Cohort H)
Presenter: Dominique Berton-Rigaud
Session: Poster session 11
756P - First-in-human phase I study of a novel claudin 6 (CLDN6) targeted antibody drug conjugate (ADC) TORL-1-23
Presenter: Gottfried Konecny
Session: Poster session 11
757P - The efficacy and safety of recombinant human adenovirus type 5 (H101) intra-tumor therapy in patients with recurrent or metastatic cervical cancer: A prospective, open-label, single-arm study
Presenter: Qiying Zhang
Session: Poster session 11